Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and internationally. It operates through Specialty and Primary Care; and Rare Diseases segments. The company develops REC 0545 for acute decompensation in m… Read more
Recordati Industria Chimica e Farmaceutica S.p.A. (RICFY) - Total Assets
Latest total assets as of September 2025: $5.30 Billion USD
Based on the latest financial reports, Recordati Industria Chimica e Farmaceutica S.p.A. (RICFY) holds total assets worth $5.30 Billion USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Recordati Industria Chimica e Farmaceutica S.p.A. - Total Assets Trend (2019–2024)
This chart illustrates how Recordati Industria Chimica e Farmaceutica S.p.A.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Recordati Industria Chimica e Farmaceutica S.p.A. - Asset Composition Analysis
Current Asset Composition (December 2024)
Recordati Industria Chimica e Farmaceutica S.p.A.'s total assets of $5.30 Billion consist of 29.1% current assets and 71.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 6.3% |
| Accounts Receivable | $516.74 Million | 10.1% |
| Inventory | $506.45 Million | 9.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $2.51 Billion | 49.0% |
| Goodwill | $797.08 Million | 15.5% |
Asset Composition Trend (2019–2024)
This chart illustrates how Recordati Industria Chimica e Farmaceutica S.p.A.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Recordati Industria Chimica e Farmaceutica S.p.A.'s current assets represent 29.1% of total assets in 2024, an increase from 28.8% in 2019.
- Cash Position: Cash and equivalents constituted 6.3% of total assets in 2024, down from 6.7% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 63.0% of total assets, an increase from 61.0% in 2019.
- Asset Diversification: The largest asset category is intangible assets at 49.0% of total assets.
Recordati Industria Chimica e Farmaceutica S.p.A. Competitors by Total Assets
Key competitors of Recordati Industria Chimica e Farmaceutica S.p.A. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
|
Zhejiang Zhenyuan Share Co Ltd
SHE:000705
|
China | CN¥3.03 Billion |
|
Hunan Jingfeng Pharmaceutical
SHE:000908
|
China | CN¥877.99 Million |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
|
China | CN¥2.58 Billion |
|
Zhejiang Haisen Pharmaceutical Co. Ltd. A
SHE:001367
|
China | CN¥1.52 Billion |
|
Yifan Xinfu Pharmaceutical Co Ltd
SHE:002019
|
China | CN¥13.11 Billion |
|
Guangdong Jiaying Pharmaceutical Co Ltd
SHE:002198
|
China | CN¥774.73 Million |
|
PharmGen Science Inc
KO:004720
|
Korea | ₩331.46 Billion |
Recordati Industria Chimica e Farmaceutica S.p.A. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Recordati Industria Chimica e Farmaceutica S.p.A. generates 0.46x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Recordati Industria Chimica e Farmaceutica S.p.A. generates $8.11 in net profit.
Recordati Industria Chimica e Farmaceutica S.p.A. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.64 | 1.38 | 1.60 |
| Quick Ratio | 1.16 | 0.93 | 1.08 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $669.84 Million | $ 348.90 Million | $ 464.51 Million |
Recordati Industria Chimica e Farmaceutica S.p.A. - Advanced Valuation Insights
This section examines the relationship between Recordati Industria Chimica e Farmaceutica S.p.A.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.86 |
| Latest Market Cap to Assets Ratio | 0.31 |
| Asset Growth Rate (YoY) | 22.0% |
| Total Assets | $5.13 Billion |
| Market Capitalization | $1.57 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Recordati Industria Chimica e Farmaceutica S.p.A.'s assets below their book value (0.31 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Recordati Industria Chimica e Farmaceutica S.p.A.'s assets grew by 22.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Recordati Industria Chimica e Farmaceutica S.p.A. (2019–2024)
The table below shows the annual total assets of Recordati Industria Chimica e Farmaceutica S.p.A. from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $5.13 Billion | +22.01% |
| 2023-12-31 | $4.21 Billion | +5.23% |
| 2022-12-31 | $4.00 Billion | +41.99% |
| 2021-12-31 | $2.82 Billion | +3.86% |
| 2020-12-31 | $2.71 Billion | -3.46% |
| 2019-12-31 | $2.81 Billion | -- |